{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacokinetic+study&page=19",
    "query": {
      "intervention": "Pharmacokinetic study",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 2549,
    "total_pages": 255,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacokinetic+study&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacokinetic+study&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T03:13:39.626Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02212951",
      "title": "Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "BIOD-531",
          "type": "DRUG"
        },
        {
          "name": "Humalog Mix 75/25",
          "type": "DRUG"
        },
        {
          "name": "Humulin R U-500",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biodel",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02212951"
    },
    {
      "nct_id": "NCT03300557",
      "title": "Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Hyperplasia",
        "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia",
        "Endometrial Carcinoma",
        "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma",
        "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2017-11-15",
      "completion_date": "2025-08-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300557"
    },
    {
      "nct_id": "NCT01986894",
      "title": "A Phase 1 QT Study in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Pharmacology, Healthy Volunteer Study"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2013-10-18",
      "completion_date": "2013-12-02",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01986894"
    },
    {
      "nct_id": "NCT03582553",
      "title": "Safety and Pharmacokinetics of an Extract of Naringenin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Safety Issues",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Naringenin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-05-25",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582553"
    },
    {
      "nct_id": "NCT01829919",
      "title": "Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postmenopausal Symptoms"
      ],
      "interventions": [
        {
          "name": "Brisdelle (paroxetine mesylate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noven Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2011-07",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-15",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829919"
    },
    {
      "nct_id": "NCT06711640",
      "title": "A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Withdrawal (Disorder)",
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "LUCEMYRA (lofexidine) tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "USWM, LLC (dba US WorldMeds)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-06",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06711640"
    },
    {
      "nct_id": "NCT01227590",
      "title": "Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Interactions",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-02",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-07",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227590"
    },
    {
      "nct_id": "NCT01199718",
      "title": "Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CX-4945",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cylene Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-09",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-06-15",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 6,
      "location_summary": "Kettering, Ohio • Portland, Oregon • Springfield, Oregon + 3 more",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199718"
    },
    {
      "nct_id": "NCT00510718",
      "title": "A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MDV3100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 140,
      "start_date": "2007-07-23",
      "completion_date": "2018-04-02",
      "has_results": true,
      "last_update_posted_date": "2019-10-03",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 9,
      "location_summary": "Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00510718"
    },
    {
      "nct_id": "NCT02217618",
      "title": "A Study of LY2409021 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "LY2409021",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-08",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-29",
      "last_synced_at": "2026-10-20T03:13:39.626Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02217618"
    }
  ]
}